Company: INDP
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001641172-25-023333
Chunk: 82

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 2
Chunk 82
---
, but not limited to:

    ●
    the
    scope, progress, results and costs of preclinical studies and clinical trials;

    ●
    the
    scope, prioritization and number of our clinical trials and other research and development programs;

    ●
    the
    amount of revenues we receive under future licensing, collaboration, development and commercialization arrangements with respect
    to our product candidates;

    ●
    the
    impact of any pandemic, epidemic or other future health crisis on our business and operations;

    ●
    the
    costs of the development and expansion of our operational infrastructure;

    ●
    the
    costs, timing and outcome of regulatory review of our product candidates;

    ●
    the
    ability of us, or our collaborators, to achieve development milestones, marketing approval and other events or developments under
    our potential future licensing agreements;

    ●
    the
    costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;

    ●
    the
    costs and timing of securing manufacturing arrangements for clinical or commercial production;

    ●
    the
    costs of contracting with third parties to provide sales and marketing capabilities for us or establishing such capabilities ourselves;

    ●
    the
    costs of acquiring or undertaking development and commercialization efforts for any future products, product candidates or technology;

    ●
    the
    magnitude of our general and administrative expenses; and

    ●
    any
    cost that we may incur under future in- and out-licensing arrangements relating to one or more of our product candidates.

Identifying
potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process
that takes many years to complete, and we may never generate the necessary data or results required to obtain marketing approval and
achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues,
if any, will be derived from sales of product candidates that we do not expect to be commercially available for the next couple of years,
if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional
financing may not be available to us on acceptable terms, or at all. For example, the trading prices for our and other biopharmaceutical
companies’ stock